Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: Thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin

European Journal of Haematology

Volumn 84, Issue 6, 2010, Pages 484-492

  Cini, Michela ^a   Zamagni, Elena ^b   Valdré, Lelia ^c   Palareti, Gualtiero ^a   Patriarca, Francesca ^d   Tacchetti, Paola ^b   Legnani, Cristina ^a   Catalano, Lucio ^d   Masini, Luciano ^e   Tosi, Patrizia ^b   Gozzetti, Alessandro ^f   Cavo, Michele ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

Multiple myeloma; Thalidomide dexamethasone; Thrombophilia thromboprophylaxis; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DEXAMETHASONE; PROTHROMBIN; THALIDOMIDE; WARFARIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; DEXAMETHASONE; FACTOR V; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTHROMBIN; RISK FACTORS; THALIDOMIDE; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77952647321     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01434.x     Document Type: Article

References (32)

1. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003 29: 275 282.
2. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002 100: 1168 1171.
3. Rus C, Bazzan M, Palumbo A, Bringhen S, Boccadoro M. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004 2: 2063 2065.
4. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002 100: 2272 2273.
5. Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb 2003 33 (Suppl. 1 15 8.
6. Potenza L, Luppi M, Morselli M, Saviola A, Ferrari A, Riva G, Longo G, Marietta M, Torelli G. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thromb Haemost 2004 91: 834 836.
7. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002 13: 187 192.
8. Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003 123: 959.
9. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106: 35 9.
10. Cavo M, Di Raimondo F, Zamagni E, et al. Short-Term Thalidomide Incorporated into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison with Double Autotransplantation for Multiple Myeloma. J Clin Oncol 2009 27: 5001 5007.
11. Talamo GP, Ibrahim S, Claxton D, Tricot G, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 2009 20: 337 339.
12. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009 145: 151 163.
13. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Br J Haematol 2003 4: 379 398.
14. De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994 72: 880 886.
15. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004 89: 1347 1351.
16. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996 348: 423 428.
17. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008 112: 4924 4934.
18. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006 134: 399 405.
19. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003 1: 445 449.
20. Yigit E, Gonullu G, Yucel I, Turgut M, Erdem D, Cakar B. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008 19: 602 607.
21. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001 115: 3 12.
22. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988 332: 83 5.
23. MacCallum PK, Thomson JM, Poller L. Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thromb Haemost 1990 64: 511 515.
24. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr., Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990 112: 423 428.
25. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994 343: 886 889.
26. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004 126: 715 721.
27. Weber D, Ginsberg C, Walker P, Oholendt M, Rankin K, Gavino M, Delasalle K, Alexanian R. Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). Blood 2002a 100: 808 809.
28. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006 108: 2159 2164.
29. Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, Westveer PH, Sonneveld P, Goldschmidt H, Lokhorst HM. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004 18: 2044 2046.
30. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 22: 414 423.
31. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007 25: 5490 5505. (Pubitemid 350232226) (Pubitemid 350232226)
32. Cavo M, Palumbo A, Bringhen S, et al. A phase III study of enoxaparin versus low-dose of warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide- containing regimens. Blood 2008 112: 3017.